Summary
Thermo Fisher Scientific Inc. (TMO) reported its financial results for the nine months ended September 28, 2013, showcasing revenue growth driven by its core segments, particularly Specialty Diagnostics. The company's strategic focus remains on augmenting internal growth with acquisitions, notably the pending acquisition of Life Technologies Corporation, valued at approximately $13.6 billion. This significant transaction is expected to be financed through a combination of equity and debt. Despite incurring costs associated with this acquisition, including bridge financing fees, Thermo Fisher demonstrated resilience with an increase in operating income and maintained a healthy cash flow from operations. Key financial metrics show a positive trajectory in revenues for the nine months ended September 28, 2013, reaching $9.62 billion, up from $9.25 billion in the prior year. The company's balance sheet reflects a substantial increase in cash and cash equivalents, largely due to financing activities related to the pending acquisition. While restructuring and other costs, including transaction-related expenses, impacted net income, the company's core operational performance remained robust, supported by productivity improvements and strategic acquisitions. Investors should note the company's commitment to growth through both organic initiatives and significant strategic M&A activity.
Financial Highlights
56 data points| Revenue | $3.19B |
| Cost of Revenue | $1.55B |
| Gross Profit | $1.35B |
| R&D Expenses | $95.90M |
| SG&A Expenses | $848.50M |
| Operating Expenses | $2.80B |
| Operating Income | $392.10M |
| Interest Expense | $64.30M |
| Net Income | $317.60M |
| EPS (Basic) | $0.88 |
| EPS (Diluted) | $0.86 |
| Shares Outstanding (Basic) | 361.20M |
| Shares Outstanding (Diluted) | 367.30M |
Key Highlights
- 1Consolidated revenues for the nine months ended September 28, 2013, increased to $9.62 billion from $9.25 billion in the prior year, indicating consistent top-line growth.
- 2The company announced a significant agreement to acquire Life Technologies Corporation for approximately $13.6 billion, signaling a major strategic expansion initiative.
- 3Thermo Fisher Scientific reported a substantial increase in cash and cash equivalents to $1.85 billion as of September 28, 2013, up from $0.81 billion at the end of 2012, bolstered by financing activities.
- 4Operating income for the nine months ended September 28, 2013, grew to $1.15 billion, up from $1.08 billion in the same period last year, demonstrating improved profitability.
- 5The company incurred significant restructuring and other costs, including approximately $130 million in the first nine months of 2013, partly related to streamlining operations and transaction costs for the Life Technologies acquisition.
- 6Despite the substantial acquisition-related expenses and restructuring costs, diluted earnings per share for the nine months ended September 28, 2013, were $2.56, showing a slight increase from $2.18 in the prior year.
- 7The company continues to invest in its core segments, with Specialty Diagnostics showing strong revenue growth of 9% for the nine months ended September 28, 2013.